BioSpace News Archive

MiNK Therapeutics, Inc. (NASDAQ: INKT) today announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the American Association for Cancer Research (AACR) Meeting in San Diego, CA.

Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a research collaboration with the Food and Drug Administration (FDA).

Longeveron Inc. announced the pricing of a public offering of 2,234,043 shares of the Company’s Class A common stock and warrants to purchase up to 2,234,043 shares of Class A common stock at a combined offering price of $2.35 per share and associated warrant.

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced that preclinical data for the company’s lead program, NST-628, were featured in an oral presentation in the “New Drugs on the Horizon” series at the American Association for Cancer Research (AACR) Annual Meeting.

The global allogeneic cell therapy devices market is growing at a strongest CAGR of 25.28% from 2023 to 2032.

According to Vision Research Reports, the global next generation sequencing market size was estimated at around USD 8.43 billion in 2023 and it is projected to hit around USD 60.18 billion by 2033, growing at a CAGR of 21.72% from 2024 to 2033.

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing authorization approval by National Medical Products Administration (NMPA) (Drug Approval Number: [GYZZ]S20240010).

Edison Oncology Holding Corp. (“Edison Oncology”), a privately held biopharmaceutical company, today announced the presentation of positive interim data from the company’s ongoing multicenter Phase 1/2a clinical trial of Orotecan (oral irinotecan HCL, VAL-413) at the American Association of Cancer Research (AACR) annual meeting.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.

Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present more than 70 abstracts and sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options as well as share their expertise on molecular profiling and the microbiome at the AACR Annual Meeting, which started April 5 and ends April 10 in San Diego.